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Uppsala University, Uppsala, SwedenObjectives. The aim of this study was to analyze the cellular sources for the neointima and the cell type that is lining the
lumen in artificial grafts implanted in pigs.
Materials and methods. We used polytetrafluoroethylene grafts as bypasses from the common to the external iliac arteries.
The animals were sacrificed after 1, 4, 7, 14, 21, 30, 60 and 90 days. Morphological, immunohistochemical and electron
microscope assessments were made.
Results. After 7 days a circumferential neoadventitia was formed. At day 14 isolated cellular islets of proliferating cells were
observed on the luminal side of the graft without connection to the neoadventitia or the adjacent arteries. In the anastomotic
regions at day 14 we observed an isolated neointima in contact with the adjacent artery. The cells lining the lumen had
characteristics of both smooth muscle cells and endothelial cells.
Conclusions. Our study suggests that in artificial porcine grafts, the perivascular tissue, the blood and the adjacent artery
contribute to the formation of the neointima. The luminal surface is covered by a hybrid cell with both smooth muscle cell and
endothelial cell properties.Keywords: Cellular sources; Neointima; PTFE graft; Hybrid cell; Pig.Progressive atherosclerosis with symptoms secondary
to ischemia is the main reason for vascular interven-
tions in humans. When blood flow is restored with
bypass surgery, approximately 20% of implanted
grafts develop stenoses within a year.1,2 The formation
of a neointima is one of the reasons for the narrowing.
Occlusion of bypass grafts is usually a sudden
consequence of thrombosis with a relapse of previous
symptoms. In the clinical setting the negative effect of
the neointima and thrombus formation is most
pronounced in artificial grafts.3
Different cellular sources for the neointima have
been observed in animal models. In a mouse vein graft
model both the donor vein and the recipient mouse
participated in the neointimal formation, indicating a
potential importance of the perivascular tissue, blood
borne cells and the adjacent artery.4 The perivascular
tissue and the adventitia have been demonstrated to
contribute to the neointima in a pig model5,6 anding author. Dr Erney Mattsson, Department of Vas-
, Sahlgrenska University Hospital, Bruna stra˚ket 11B,
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different rodent models of intimal thickening.7,8 Little is
known about the cellular sources for neointimal for-
mation in artificial graftswhich, is the focus of this study.
Long-term patency rates of artificial grafts are
influenced by the cell type lining the lumen. Human
artificial grafts do not seem to form an endothelial lining
and ex vivo seeding of prosthetic conduits with endo-
thelial cells (ECs), dramatically improves the long-term
patency rates in man.9 In contrast to humans, animal
models of artificial grafts heal with an endothelial
coverage.10,11 The aim of this study was to analyze the
cellular sources for the neointima and the cell type along
the lumen in artificial grafts using a porcine model.MethodsAnimal model
Twenty-six male castrated domestic pigs, weighing
approximately 25 kg were used in the study.Eur J Vasc Endovasc Surg 30, 63–70 (2005)
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S. Mellander et al.64Anaesthesia was induced with intramuscular keta-
mine hydrocloride (10 mg/kg) and thiopentalnatrium
(10 mg/kg) and maintained after endotracheal intuba-
tion with a mixture of intravenously given ketamine
hydrocloride and midazolam (1000 ml NaCl with
1000 mg ketamine hydrocloride and 30 mg midazo-
lam, 200–400 ml/h). Unwrapped, 4–5 cm long, 4 mm
internal diameter, PTFE grafts (polytetrafluoroethy-
lene) (W.L. Gore and associates, Inc., Flagstaff,
Arizona, 60 mm internodal distance), were bilaterally
placed from the common to the external iliac arteries.
Anastomoses were sutured end to side using 6–0
polypropylene sutures (Davies and Geck, Danbury,
Conn). The native iliac arteries were ligated to shunt
the blood flow through the implanted grafts. Heparin
was given intravenously (400 U/kg) before clamping
and an additional dose of 200 U/kg was injected after
2 h of surgery. The wounds were infiltrated with
bupivacain hydrocloride (4 mg/kg) and each animal
was under surveillance until returned to a common
cage 2 days after surgery. Antibiotics were adminis-
tered intramuscularly (dihydrostreptomycin
6.5 mg/kg and benzylpenicillin 5 mg/kg) for a total
of 3 days. The specimens were retrieved under
terminal anaesthesia after 1, 4, 7, 14, 21, 30, 60 and 90
days by a barbiturate overdose. All animal care and
procedures were performed in accordance with state
and federal laws. Animal protocols were approved by
the ethical committees at Go¨teborg University and the
University of Lund and conformed to guidelines set
forth by national laws.Tissue samples
Both grafts were removed together with the native
vessels en bloc and flushed with isotonic saline
solution. The anastomoses including the adjacent
arteries were also retrieved. Specimens from the mid
portion of the graft, 5 mm proximal and distal to the
anastomoses and the native artery 5–10 mm from the
anastomoses were saved. The anastomoses were cut
longitudinally. The specimens were immersed in 4%
formalin, buffered with sodium phosphate, for
approximately 12 h. Dehydration was performed in a
graded series of ethanol (70, 95, 99.5%), xylene, and
finally the specimens were embedded in paraffin.
Transverse sections of 5 mm were cut onto slides.
Midgraft segments (30 day grafts) were also taken for
scanning and transmission electron microscopy
(SEM/TEM). These specimens were fixed by immer-
sion in 2% paraformaldehyde C2.5% glutaraldehyde
C0.1% sodiumazide in cacodylate buffer. Graft pieces,
5!5 mm2, intended for SEMwere postfixed accordingEur J Vasc Endovasc Surg Vol 30, July 2005to the OTOTOmethod.12 Dehydration in graded series
of alcohol was followed by infiltration with hexam-
ethyl disilazane which was allowed to evaporate till
dryness. Specimens were mounted on aluminum
stubs and were examined in a Zeiss 982 Gemini field
emission SEM, with or without previous sputter
coating with chromium. TEM samples were postfixed
with 1% OsO4 and 1% K ferrocyanide in cacodylate,
followed by uranyl staining en bloc, alcohol dehy-
dration, plastic resin infiltration, and curing. Ultrathin
sectioning was performed with a Reichert Ultracut E
ultramicrotome equipped with a diamond knife and
sections were examined in a Zeiss 902 TEM after
counterstaining with lead citrate and uranyl acetate.Morphometric analyzes
The specimens were stained with hematoxylin and
eosin for morphometric analyzes. Areas were
measured in light microscopy with Kontron Electronic
image analysing system (KS 400 version 2.0, Carl
Zeiss, Germany).Immunohistochemistry
Immunohistochemistry was performed to determine
the cellular components and proliferation index. The
specimens were de-waxed with xylene, ethanol and
phophate-buffered saline (PBS pH 7.2). For antigen
retrieval, specimens were treated with proteinase K
(DAKO, Denmark) for 5 min or microwaved in a
citrate buffer for 10 min (Proliferating Cell Nuclear
Antigen (PCNA). To block endogenous peroxidases
and nonspecific binding sites, the specimens were
incubated for 5 min with 3% hydrogen peroxide and
15 min with 5% milk powder solution (Semper,
Sweden). The following mouse monoclonal primary
antibodies were used: anti-human smooth muscle
alpha-actin (1:100, clone 1A4, DAKO), anti-human
monocytes/macrophages antibody recognizing intra-
cytoplasmatic antigen (L1 or Calprotectin) in mono-
cytes, tissue macrophages and granulocytes (1:100,
clone MAC387, Serotec, England), anti-human PCNA
(1:25, clone PC10, DAKO). Endothelial cells were
detected with a rabbit anti-human antibody against
von Willebrand factor (1:400, DAKO). The specimens
were incubated with the primary antibodies for 3 h at
room temperature and for 30 min with the secondary
antibody conjugated with horseradish peroxidase
(EnVision kit, DAKO). DAB substrate (Vector Labora-
tories) was used for visualization. Nuclei were
counterstained with hematoxylin. Control slides with
nonimmune IgG as primary antibody were included.
Cellular Sources for Neointima in PTFE Grafts 65Proliferation index
For each time point and graft a proliferative index was
calculated. Midgraft cross sections were divided by
eight lines clock-wise. Along these lines, cells were
counted in each layer (neoadventitia, graft and
neointima). A snapshot was taken (400!, light
microscopy, Zeiss, Axiocam, Germany), and further
processed in an image analysis program (Adobe
Photoshop, USA). An overlying grid was applied
and the nuclei stained with hematoxylin and the
PCNA-positive nuclei were counted manually. A
mean value was calculated from the eight measure-
ments in each layer. The proliferation index is
expressed as the percentage PCNA-positive cells of
the total number of cells. All degrees of staining of cells
with the antibody recognizing PCNAwere regarded as
positive cells, which might give false high indices.Leukocyte count (monocytes, macrophages and
granulocytes)
A leukocyte count was performed for each time point
in the graft material. The specimens were manually
counted at four different locations (clock-wise at 12, 3,
6 and 9) using light microscopy (400!magnification).
The mean of the four values was used.ResultsFig. 1. The graft lumen is oriented upwards in pictures (A)–
(D). Scale bar is 100 mm.Magnification in panels A, B and C is
identical. (A) Day 7. A neoadventitia covers the outside of
the graft. Proliferating, PCNA-positive brown cells, are
invading the internodal spaces. (B) Cellular formations at
the luminal side of the graft at day 14. Cells staining brown
are PCNA-positive. No cellular connection to the neoadven-
titia is present, indicating a potential contribution from
blood-borne cells. (C) Luminal cells staining positive for a-
actin at day 21 (brown colour). There is still no connection to
the neoadventitia from these cellular islands. (D) A
longitudinal section of an anastomosis at day 14. The native
artery has cellular contact with the neointima, indicating a
contribution from this cellular source. There is no transmural
growth through the graft. Arrowheads mark the inner
surface of the graft. The red areas within the graft are
formed by red blood cells. The black arrow points at the end
of the internal elastic lamina of the artery.Morphology and morphometric analyzes
At day 4 a patchy perigraft cell layer, a neoadventitia,
had developed which became circumferential after 1
week. Cellular invasion from the neoadventitia into
the internodal spaces of the grafts was seen at day 7
and the ingrowth was progressing towards the lumen
at day 14 (Fig. 1(A)). At the same time we found
cellular islets at the luminal side of the graft without
connection to cells from the outside. In these for-
mations a number of cells were PCNA-positive but all
were alpha-actin negative (Fig. 1(B)). At day 21 patchy
areas of an alpha-actin positive neointima was
observed without connection to the neoadventitia
(Fig. 1(C)). In the anastomotic regions, at day 14, a
neointima was present before any transmural growth
through the graft could be seen. These cells were in
cellular contact to the adjacent artery (Fig. 1(D)).
The neointima in the mid-graft sections became
circumferential after 1 month with a cellular con-
tinuum to the neoadventitia. The area of the neointima
progressed with further narrowing of the lumen at 3months (Figs. 2(C) and 4(A)). There were no obvious
differences between the areas at the mid-graft,
proximal graft or distal graft at any timepoint. At 3
months 5 out of 6 grafts were occluded with a
thrombus inside a small lumen (Table 1).Eur J Vasc Endovasc Surg Vol 30, July 2005
Fig. 2. (A) The number of leukocytes in the graft-fabrics at
different time-points (per sightfield in 400!magnificationZ
0.28 mm2). (B) Percentage proliferating cells in the neoad-
ventitia, graft and neointima at different time-points (per
sightfield in 400! magnification). (C) Area of neointima.
Data are presented as mean GSD.
S. Mellander et al.66ImmunohistochemistryLeukocytes (granulocytes, monocytes and macrophages)
The vast majority of cells at day 1 stained positive for
leukocytes in the graft. One week later leukocytes
were substantially reduced in number. At day 21
almost no leukocytes were found inside the graft but
could still be found as a lining of the luminal surface
and frequently on top and partly within isolated areasTable 1. The number of grafts analyzed and the occlusion rate at eac
Day 1 4 7 14
Analyzed
grafts
6 8 10 10
Occluded
grafts
0 0 0 0
Eur J Vasc Endovasc Surg Vol 30, July 2005of neointima (Fig. 3(A)). Positive cells were also seen in
the outer layer of the neoadventitia. After 30, 60 and 90
days leukocytes could only sporadically be found in
the specimen (Fig. 2(A)).
Alpha-actin
Most cells in the neoadventitia at day 7 stained
positive for alpha-actin and so did cells infiltrating
the graft from the outside at day 14. The isolated
luminal cell islets in the mid-graft at day 14 were
negative for alpha-actin. At day 21 these luminal areas
stained positive underneath and among leukocytes
(Fig. 3(A) and (B)). At days 30, 60 and 90 there was an
even distribution of alpha-actin positive cells in all
layers (neoadventitia, graft and neointima).
Proliferating cell nuclear antigen (PCNA)
At day 1 no proliferation (PCNA-positive cells) were
detected. Highest relative activity was reached inside
the graft at its outer border at day 7. In the
neoadventitia at days 4, 7 and 14 most activity was
localized towards the graft-fabrics. At day 14 cells
migrating into the graft from the neoadventitia were
also positive, however, at this timepoint we also found
isolated cellular areas at the luminal side (Fig. 1(B)). At
day 30 PCNA-positive cells were found in all layers.
Activity successively decreased at later time-points
(Fig. 2(B)).
von Willebrand factor
Positive staining for von Willebrand factor first
appeared in capillaries at day 7 in the neoadventitia.
When the neointimal thickening was fully established
capillaries could be seen in all layers (neoadventitia,
graft and neointima) but none with proven contact to
the luminal surface (Fig. 4(A)). Luminal cells did not
stain positive for von Willebrand factor at any time-
point (Fig. 4(B)). To exclude a false positive signal from
platelets, we assured that endothelial cells in capil-
laries had staining on both sides of their nuclei
(luminal and abluminal) (Fig. 4(C)).
Scanning electron microscopy
The luminal surfaces of the grafts were covered with a
continuous epithelium that on overview resembled
the morphology of a large vessel endotheliumh time-point (nZ52)
21 30 60 90
4 4 4 6
0 1 1 5
Fig. 3. Neointima at day 21 without connection to the
neoadventitia. Scale bar is 100 mm. Arrowheads point at the
graft. (A) Brown stained cells are leukocytes (monocytes/-
macrophages or granulocytes), positive for anti-human
monocytes/macrophages antibody, clone MAC387. The
smaller panel shows the cells close to the lumen in higher
magnification. Leucocytes are present along the lumen and
partly within the neointima. (B) The majority of cells in the
neointima except the luminal lining are positive for a-actin.
The smaller panel shows the luminal cells in higher
magnification.
Fig. 4. Detection of endothelial cells with von Willebrand
factor (brown colour). Scalebar is 100 mm in A. Arrowheads
point at the graft. (A) Arrows point at stained capillaries
while cells at the luminal surface show no staining. Arrow-
heads indicate graft borders. (B) Luminal cells in 400!
magnification showing no positive staining for von Will-
ebrand factor. (C) Capillaries in the internodal space of the
graft are positive for von Willebrand factor (1000!
magnification).
Cellular Sources for Neointima in PTFE Grafts 67(Fig. 5(A)). A closer examination demonstrated that
the intercellular organisation varied and the dominant
flattened cell type left defects occupied by bulging
portions of cells from a deeper location (Fig. 5(A),
detailed view). These latter observations are usually
not seen in a large vessel endothelium. It was not
possible to identify orifices of micro vessels commu-
nicating with the graft lumen.Transmission electron microscopy
TEM was performed on transversely sectioned neoin-
timas. The thickness of the surface cells varied (Fig.
5(B)). Voluminous cells had an abundance of orga-
nelles and subplasmalemmal microfilaments, as inSMCs, while others were flattened and dense. Some
cells were forming a pseudopod-like structure, push-
ing the resident surface cells aside, as if they were
migrating from a subendothelial to an endothelial
position (Fig. 5(B)). In these the cells the microfila-
ments were located at the abluminal part of the cell.
The continuity of the luminal cell lining was main-
tained by close cell-to-cell contacts formed between
the assumed new and older cells.Eur J Vasc Endovasc Surg Vol 30, July 2005
Fig. 5. (A) Scanning electron micrographs of the luminal
surface of the graft. Overview. Cells resembling the
cobblestone pattern of a large vessel endothelium. Scattered
protruding cells are seen (white arrows). Detailed view
showing a cleft-like contact between surface cells (white
arrowheads). Arrows point at cells protruding from below.
(B) Transmission electron micrograph of the luminal cells.
Two dark cells form the luminal surface. These are extremely
attenuated (arrowheads). A bright and organelle-rich cell
projects with a pseudopod-like process (open star) into the
lumen through the interval between the dark cells (arrows).
The extracellular space between the cellular layers is limited
(nuclei, labelled with N).
S. Mellander et al.68Discussion
In the present study, we investigated which cellular
sources participated in the neointimal formation in
PTFE-grafts. Our observations suggest that the peri-
vascular tissue and the blood formed the neointima in
mid-graft sections, while the adjacent artery seemed to
be a main cellular source in the anastomotic regions.
Our aim was to uncover all possible cellular sources,
which can participate in the formation of a neointima.
We did not exclusively focus on the anastomoses, even
if these areas may be important in the clinical
situation.
The cells lining the lumen had characteristics
connected to SMCs when analyzed in detail, but had
an appearance on SEM similar to ECs. The mostEur J Vasc Endovasc Surg Vol 30, July 2005dominant cell type in the present study was alpha-
actin positive cells. The majority of the cells appeared
on the external side of the graft and then continuously
grew through the graft fabrics and formed a neoin-
tima. This suggests the perivascular tissue as one
origin of the intimal SMCs. Similar findings have been
reported in other studies. Both in a vein graft and in a
balloon-injury porcine model, BrdU-labelled fibro-
blasts in the adventitia/perivascular tissue migrated
and participated in the formation of a neointima.5,6
Recently, it has also been observed in sheep that the
neoadventitia is important for remodeling after
implantation of synthetic patches.13
In the anastomoses a neointima was present before
any transmural growth through the interstices of the
graft was established. The neointima had continuous
cellular contact to the recipient artery. This suggests
the adjacent artery as a main cellular source for the
neointima in the anastomoses. However, recruitment
of neointimal cells from the perivascular tissue
through the interspace between the graft and the
artery or from the blood cannot be excluded.
At day 14 isolated islets with proliferating cells
were seen on the luminal side of the graft. At this time-
point we could not find any cellular continuity from
the neoadventitia or the adjacent arteries to these
neointimal islets. Since, the graft fabrics do not
harbour any cells to begin with, we see the blood as
the most probable source for these cellular formations.
Early in the healing process we noticed a pronounced
infiltration of leukocytes into the graft, which was
followed in sequence by cellular proliferation and
formation of a neointima. Leukocytes were present
within and covered the luminal thickening at day 21.
Different studies have suggested that monocytes/ma-
crophages have the ability to change their phenotypes
into SMC-like cells.14,15 It has also been shown in pig
that macrophages populated the neointima after
thermal vascular injury and that these cells most likely
were the precursors of neointimal myofibroblasts.16
Recent studies suggest that the bone marrow also can
provide circulating progenitors for vascular SMCs.7,8,
17 The inflammatory response in our model is also seen
in angioplasty, vein grafts and transplant allografts
suggesting that similar initial mechanisms are
involved in other reparative situations in the vascu-
lature. Besides being a cellular source by themselves,
leukocytes also might have started the recruitment of
SMCs and the formation of a neointima through
secretion of cytokines and growth factors.18,19
While other animal models of prosthetic grafts heal
with endothelialization,10,11,20 this is not the case in
man.21–23 Seeding of artificial grafts with ECs
improves the patency rates in humans, which supports
Cellular Sources for Neointima in PTFE Grafts 69the importance of the luminal cell type.9 The luminal
surface cells in our study exhibited some character-
istics of endothelium when analyzed with SEM. On
the other hand, the cells did not express the endo-
thelial marker von Willebrand Factor (vWF). In pigs it
is known that vWF is not universally distributed in
various endothelial beds. vWF is proven to be present
in the distal abdominal aorta, the vaso vasorum, the
thoracic aorta and the pulmonic artery.24 Avariation in
distribution could be one possible explanation why
the luminal cells in our study did not stain positive. On
the other hand, capillaries in the neoadventitia, the
graft material and the formed intimal hyperplasia (IH)
stained positive in the same specimens. TEM analysis
showed that the luminal cells contained subplasma-
lemmal microfilaments, which are normally found in
SMCs. Moreover, the cellular migration had an
implied direction from the pool of SMCs in deeper
layers towards the surface. One explanation for the
contrasting observations is that the luminal cells were
SMCs, which had achieved some characteristics
similar to endothelial cells.25 A hybrid cell of this
kind has so far not been described in humans. We are
currently looking at graft explants to see if such a cell
exists in man. As a combined result of the neointimal
formation and thrombosis, 5 out of 6 grafts were
occluded at day 90. The high occlusion rate in our
study could be explained by either the intimal
hyperplasia itself or the luminal coverage of cells
with a higher thrombogenicity than true ECs.9
This paper demonstrates several potential cellular
sources for IH. A combined inhibition of these sources
seems to be a logical approach to prevent IH. Systemic
treatments have shown little effects on IH. One reason
might be the inability to deliver sufficient drug to the
vessel wall. Other reasons are the side effects and
tolerability of the drug.26 Therefore, local prevention
appears to be the best approach to the unsolved issue
of IH. Drug eluting stents have shown promising
results after percutaneous coronary interventions both
in animal models and in man.27
In bypass surgery with artificial grafts, the perivas-
cular contribution to the neointima can be inhibited by
wrapping and low porosity. These grafts are already in
use but there are few reports of their efficacy.28 Local
gene therapy using a matrix gel around the anasto-
moses could be a future tool to inhibit IH.29 The IH at
the anastomotic sites has other potential cellular
sources. The adjacent, native artery and perhaps the
blood are the remaining alternatives. The contribution
from the adjacent artery might be influenced by local
therapy such as brachytherapy or photodynamic
therapy.30,31 We are currently studying he latter
modality. The blood as a cellular source needs furtherinsight into the basic biology before any preventional
undertakings can be recommended.
In conclusion, we suggest that different cellular
sources such as the perivascular tissue, the blood and
the adjacent artery contribute to the formation of the
neointima in artificial porcine grafts and that a hybrid
cell with characteristics of both SMCs and ECs is lining
the lumen. This model gives us a potent tool for
further studies on IH.Acknowledgements
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